About: Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection
Creator	Ricordi, Camillo Alejandro, Rodolfo Caprio, Massimiliano Fabbri, Andrea Infante, Marco
Source	Medline; PMC
abstract	INTRODUCTION: Over the last few months, coronavirus disease 2019 (COVID-19) pandemic caused by the novel coronavirus SARS-CoV-2 has posed a serious threat to public health on a global scale. Given the current lack of an effective vaccine, several drugs have been repurposed for treatment and prophylaxis of COVID-19 in an attempt to find an effective cure. AREAS COVERED: The antimalarial drug hydroxychloroquine (HCQ) initially garnered widespread attention following the publication of preliminary results showing that this drug exerts an anti-SARS-CoV-2 activity in vitro. EXPERT OPINION: To date, clinical evidence suggests lack of benefit from HCQ use for the treatment of hospitalized patients with COVID-19. In such patients, HCQ also appears to be associated with an increased risk of QT interval prolongation and potentially lethal ventricular arrhythmias. Therefore, FDA has recently revoked the Emergency Use Authorization (EUA) for emergency use of HCQ and chloroquine to treat COVID-19. Conversely, whether HCQ use may represent an effective prophylactic strategy against COVID-19 is a separate question that still remains to be answered. In addition, relevant aspects regarding the potential risks and benefits of HCQ need to be clarified, in pursuit of a rational use of this drug in the COVID-19 pandemic era.
has issue date	2020-08-16(xsd:dateTime)
bibo:doi	10.1080/14787210.2020.1799785
bibo:pmid	32693652
has license	no-cc
sha1sum (hex)	c3c5461f625e7c6efb0168128f6a6cc5e627783c
schema:url	https://doi.org/10.1080/14787210.2020.1799785
resource representing a document's title	Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection
has PubMed Central identifier	PMC7441799
has PubMed identifier	32693652
schema:publication	Expert review of anti-infective therapy
resource representing a document's body	covid:c3c5461f625e7c6efb0168128f6a6cc5e627783c#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'HCQ' named entity 'SARS-CoV-2' named entity 'hydroxychloroquine' named entity 'ventricular arrhythmias' named entity 'volume of distribution' named entity 'HCQ' named entity 'G6PD' named entity 'membrane fusion' named entity 'pathogenesis' named entity 'chloroquine' named entity 'antigen processing' named entity 'scientific community' named entity 'organelles' named entity 'HCQ' named entity 'HCQ' named entity 'COVID' named entity 'vitamin' named entity 'SARS-CoV-2' named entity 'sample size' named entity 'COVID' named entity 'retinopathy' named entity 'randomized controlled trial' named entity 'double-blind, placebo-controlled' named entity 'SARS-CoV-2' named entity 'ClinicalTrials.gov' named entity 'proteases' named entity 'lysosomal' named entity 'cleavage' named entity 'prolonged QT interval' named entity 'zinc' named entity 'COVID-19' named entity 'neuropathy' named entity 'HCQ' named entity 'gene' named entity 'ClinicalTrials.gov' named entity 'prophylactic' named entity 'COVID' named entity 'metabolic' named entity 'COVID' named entity 'cardiac arrhythmias' named entity 'healthcare workers' named entity 'plasma' named entity 'intracellular' named entity 'HCQ' named entity 'Th2' named entity 'case-control study' named entity 'ACE2' named entity 'host cells' named entity 'FDA' named entity 'polymerase chain reaction' named entity 'toxicity' named entity 'clinical trials' named entity 'host cell' named entity 'HMGB1' named entity 'HCQ' named entity 'HCQ' named entity 'healthcare systems' named entity 'chemoprophylaxis' named entity 'COVID' named entity 'COVID' named entity 'PEP' named entity 'inflammation' named entity 'coronaviruses' named entity 'intubation' named entity 'case-control study' named entity 'COVID-19' named entity 'electrocardiography' named entity 'COVID-19' named entity 'HCQ' named entity 'risk factors' named entity 'prophylaxis' named entity 'MHC' named entity 'hypomagnesemia' named entity 'post-exposure prophylaxis' named entity 'TMPRSS2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software